39 results about "Neovascular glaucoma" patented technology

Indazole compounds that modulate and / or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Indazole compounds that modulate and / or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Indazole compounds that modulate and / or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and / or reversing ocular diseases related with ocular neovascularization. Partcularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).

A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (Dll4) activity to a subject in need thereof. In one embodiment, the agent is an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor. The method of the invention is useful for treating eye disorders such as ischemic retinopathy, diabetic retinopathy, age related macular degeneration, corneal neovascularization, neovascular glaucoma, or retinopathy of prematurity. The method is also useful or treating ischemic or vascular disorders such as ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension.

Indazole compounds that modulate and / or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

RNA interference, is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

Indazole compounds that modulate and / or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Indazole compounds that modulate and / or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses increases in retinal blood vessel permeability induced by VEGF and therefore can be used as an active component in therapeutic agents or prophylactic agents for a variety of ocular diseases to which VEGF contributes, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion, and neovascular glaucoma.

The invention provides a biological retina, which is applied to tissue repair in the field of ophthalmological department. The tissue repair includes glaucoma trabeculectomy, a neovascular glaucoma surgery, uveitic glaucoma, a pterygium surgery, a strabismus surgery, a nasolacrimal duct operation, an orbital surgery, an ocular plastic surgery, a conjunctival scar tissue reconstruction surgery, a burn repair surgery and a corneal ulcer surgery; and the preparation method comprises the following steps: preparing a high-purity type I collagen and glacial acetic acid water solution according to a preset proportion and emulsifying; and vacuumizing the emulsified slurry and freeze-drying the slurry so as to obtain a collagen film having a three-dimensional porous structure. The biological retina disclosed by the invention has beneficial effects that the prepared biological retina, which takes the collagen, as a major ingredient, is good in biocompatibility and biodegradability and is capable of controlling an inflammatory reaction; the high-purity collagen is free from antigenicity and repellency; by virtue of the three-dimensional porous structure, the random and discrete hyperplasia of fibroblasts is guided; and the biological retina can inhibit conjunctival scars and conjunctival contraction, and can keep normal intraocular pressure.

Indazole compounds that modulate and / or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Indazole compounds that modulate and / or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

Indazole compounds that modulate and / or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

Chemical compounds that are derivatives of 2H[1]-benzothiepino[5,4-c]pyrazole, 2H[1]-benzoxepino[5,4-c]pyrazole, 1-benzothiopyrano[4,3-c]pyrazole, 1-benzopyrano[4,3-c]pyrazole, 4,5-dihydro-2h-furano[2,3-g]indazole and 4,5-dihydro-2h-thieno[2,3-g]indazole derivatives 2H[1]-benzothiepino[5,4-c]pyrazole, [1]-benzothiopyrano[4,3-c]pyrazole, 4,5-dihydro-2H-furano[2,3-g]indazole and 4,5-dihydro-2H-thieno[2,3-g]indazole derivatives are inhibitors of protein kinase activity. Several of the protein kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic and / or edematous processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis, edema or endothelial cell hyperproliferation or hyperpermeability is a factor. Like cancer, artritis, atherosclerosis, psoriasis, hemangioma, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, corneal disease, rubeosis, neovascular glaucoma, macular degeneration, wound healing, peptic ulcer Helicobacter related diseases, fractures, diabetic retinopathy, and cat scratch fever.

The invention discloses an application of anthracene nucleus antibiotic and its pharmaceutical salt for treating neovascular glaucoma. The invention found that the anthracene nucleus antibiotic and its pharmaceutical salt have good effect on treatment of r neovascular glaucoma, and especially the anthracene nucleus antibiotics can be prepared to prolonged action preparations such as a nano preparation, a microballoon preparation, liposome and hydrogel, the toxicity of anthracene nucleus antibiotic is reduced, and the anthracene nucleus antibiotic enables ophthalmic administration, administration dosage is simultaneously enlarged, the duration time of drug effect is long, the medicament curative effect is stronger than that of the common preparations of the anthracene nucleus antibiotic, when the ophthalmic administration is carried out, the anthracene nucleus antibiotic has good treatment effect for treating retinal vein occlusion, and the blank that no medicine is good for treating neovascular glaucoma can be filled.

The invention discloses an application of combined IFA and FFA to merged DR and DI. The application method includes the following steps that 1, eye mydriasis is dropped for 30 minutes with tropicamide eye drops; 2, patients are subjected to a sodium fluorescein allergy test; 3, patients free of allergy phenomenon are subjected to IFA inspection; 4, then the patients are subjected to FFA inspection; 5, IFA inspection is repeated; 6, FFA inspection is repeated. Combined IFA and FFA inspection is compared with a past separated IFA inspection and FFA, merged-DR-and-DI patients can be comprehensively evaluated through combined-IFA-and-FFA inspection in one time of inspection, and the one-time-IFA-inspection cost is saved for all the patients. More importantly, early-merged-DR-and-DI patients can be discovered through combined-IFA-and-FFA inspection, the basis is provided for individualized treatment accordingly, and it is prevented that the illness state is evolved to blind neovascular glaucoma from NPDI or PDI.

The invention relates to a stainless steel device for permanent insertion into the sclerocorneal limbus, with different drainage and anchorage systems, enabling the aqueous humour to discharge through one or more virtual spaces from the anterior chamber to an intrascleral space in cases of simple glaucoma or to the equatorial episclera in cases of complex glaucoma, such as neovascular glaucoma. The space is virtual, not real, as in the case of the tubular device. It enables the aqueous humour to discharge slowly and continuously, minimizing the possibility of the chamber being flat or of germs penetrating through the device. Furthermore, the anchorage system is less aggressive, thus reducing the possibility of bleeding.

The present invention relates to fusion molecules and chimeric molecules comprising two components: Ang2 antagonist peptides linked to VEGF binding moieties. Further disclosed are methods of treatingcancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME), ordiabetic retinopathy (DR) in a patient using the chimeric molecules.

A traditional Chinese medicament for treating neovascular glaucoma mainly comprises the following traditional Chinese medicines by weight: 10 parts of nepeta cataria, 10 parts of white chrysanthemum, 10 parts of divaricate saposhnikovia roots, 10 parts of saiga tatarica Linnaeus, 10 parts of cortex moutan, 10 parts of radix bupleuri, 10 parts of flos carthami, 8 parts of herba lycopi, 8 parts of rhizoma chuanxiong, 5 parts of rhubarb, 12 parts of rhizoma imperatae, and 10 parts of achyranthes bidentata, and the traditional Chinese medicines are mixed and decocted to form liquid medicine. The traditional Chinese medicament can be used for dialectically treating diseases with pathogenic mechanisms of syndromes of wind-fire invading eyes and wind-phlegm invading upward and qi stagnation and blood stasis, the traditional Chinese medicines with the functions of removing heat from the liver, activating blood, clearing heat, decreasing internal heat, removing phlegm, promoting circulation and removing stasis are combined and decocted to form the medicament, and a stable curative effect is achieved.

The invention discloses a derivative containing nitrogen heterocyclic rings and application of the derivative in retinal neovascularization diseases. The derivative has the biological structural formula shown in the description, wherein R1, R2, R3 and R4 are respectively and independently selected from -H or -CN. Under the same concentration of 5microg / mL, the growth inhibition ratios of the embodiment II, the embodiment III and the embodiment IV to HRCEC are superior to a monoclonal antibody drug Avastin. By injecting the compound into a vitreous body, the formation of pathologic new vesselscan be reduced, so that the derivative of the formula I or the salt of the derivative can be used for deeply researching and developing retinal neovascularization relevant diseases such as retinal vein occlusion, proliferative diabetic retinopathy, subretinal neovascular membrane, neovascular glaucoma, retinopathy of prematurity and proliferative vitreoretinopathy.

The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

The invention provides a biological retina, which is applied to tissue repair in the field of ophthalmological department. The tissue repair includes glaucoma trabeculectomy, a neovascular glaucoma surgery, uveitic glaucoma, a pterygium surgery, a strabismus surgery, a nasolacrimal duct operation, an orbital surgery, an ocular plastic surgery, a conjunctival scar tissue reconstruction surgery, a burn repair surgery and a corneal ulcer surgery; and the preparation method comprises the following steps: preparing a high-purity type I collagen and glacial acetic acid water solution according to a preset proportion and emulsifying; and vacuumizing the emulsified slurry and freeze-drying the slurry so as to obtain a collagen film having a three-dimensional porous structure. The biological retina disclosed by the invention has beneficial effects that the prepared biological retina, which takes the collagen, as a major ingredient, is good in biocompatibility and biodegradability and is capable of controlling an inflammatory reaction; the high-purity collagen is free from antigenicity and repellency; by virtue of the three-dimensional porous structure, the random and discrete hyperplasia of fibroblasts is guided; and the biological retina can inhibit conjunctival scars and conjunctival contraction, and can keep normal intraocular pressure.

RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

It has been discovered that enterostatin inhibits angiogenesis in an in vitro adipose tissue angiogenesis model. In concentrations from about 10−6 to about 10−9 M, enterostatin effectively blocked the angiogenic response. Enterostatin will be effective in treating noncancerous and cancerous diseases that involve an increase in angiogenesis, e.g., rheumatoid arthritis, retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, and psoriasis. This, antiangiogenic activity was confirmed in two additional tissue cells lines (liver and neuronal cells) using a microarray analysis.